Amarin (AMRN) News Today → The #1 Investment of the Decade… (From Porter & Company) (Ad) Free AMRN Stock Alerts $0.91 -0.02 (-2.15%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 6, 2024 | globenewswire.comAmarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 3, 2024 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comQ2 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Reduced by Zacks ResearchAmarin Co. plc (NASDAQ:AMRN - Free Report) - Research analysts at Zacks Research lowered their Q2 2025 EPS estimates for shares of Amarin in a research report issued to clients and investors on Tuesday, April 30th. Zacks Research analyst R. Department now expects that the biopharmaceutical companMay 2, 2024 | marketbeat.comAmarin (NASDAQ:AMRN) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPSAmarin (NASDAQ:AMRN - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative return on equity of 10.47% and a negative net margin of 19.26%. During the same period in the previous year, the company posted ($0.04) EPS.May 2, 2024 | finance.yahoo.comAmarin First Quarter 2024 Earnings: EPS Beats ExpectationsMay 1, 2024 | markets.businessinsider.comAmarin’s Sell Rating Affirmed Amid US Market Challenges and Uncertain European GrowthMay 1, 2024 | finance.yahoo.comAmarin Corp PLC (AMRN) Q1 2024 Earnings: Navigating Challenges with Strategic FocusMay 1, 2024 | fool.comAmarin Plc (AMRN) Q1 2024 Earnings Call TranscriptMay 1, 2024 | investorplace.comAMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024May 1, 2024 | globenewswire.comAmarin Reports First Quarter 2024 Business Update and Financial ResultsApril 30, 2024 | markets.businessinsider.comHere's what Wall Street expects from Amarin's earnings reportApril 30, 2024 | msn.comAmarin Q1 2024 Earnings PreviewApril 28, 2024 | marketbeat.comAmarin Co. plc (NASDAQ:AMRN) Short Interest UpdateAmarin Co. plc (NASDAQ:AMRN - Get Free Report) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 15,840,000 shares, a drop of 12.1% from the March 31st total of 18,020,000 shares. Based on an average daily trading volume, of 1,680,000 shares, the days-to-cover ratio is presently 9.4 days.April 24, 2024 | finance.yahoo.comAmarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventApril 24, 2024 | globenewswire.comAmarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventApril 22, 2024 | globenewswire.comAmarin Announces Results of Annual General Meeting of ShareholdersApril 18, 2024 | seekingalpha.comAmarin Corporation: Small Signs Of Recovery May Not Be EnoughApril 15, 2024 | globenewswire.comAmarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024April 8, 2024 | finanznachrichten.deAmarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsApril 8, 2024 | globenewswire.comAmarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24April 6, 2024 | globenewswire.comNew REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsApril 3, 2024 | fool.comWhy Amarin Stock Was Rocketing Higher on WednesdayApril 3, 2024 | markets.businessinsider.comAmarin: IP Protection For VAZKEPA In Europe Now Extended Into 2039 - Quick FactsApril 3, 2024 | globenewswire.comAmarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeMarch 25, 2024 | finance.yahoo.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & ExpoMarch 25, 2024 | globenewswire.comResearch Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & ExpoMarch 16, 2024 | finance.yahoo.comAMRN Apr 2024 3.000 callMarch 8, 2024 | finance.yahoo.comAMRN Apr 2024 1.500 putMarch 7, 2024 | finance.yahoo.comAMRN May 2024 1.000 callMarch 7, 2024 | marketbeat.comFY2024 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Boosted by AnalystAmarin Co. plc (NASDAQ:AMRN - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2024 EPS estimates for shares of Amarin in a research note issued to investors on Monday, March 4th. Cantor Fitzgerald analyst L. Chen now expects that the biopharmaceutical company will earn ($0March 6, 2024 | finance.yahoo.comAMRN Mar 2024 0.500 callMarch 5, 2024 | finance.yahoo.comAmarin Full Year 2023 Earnings: Beats ExpectationsMarch 3, 2024 | marketbeat.com13D Management LLC Sells 2,579,723 Shares of Amarin Co. plc (NASDAQ:AMRN)13D Management LLC lessened its stake in shares of Amarin Co. plc (NASDAQ:AMRN - Free Report) by 63.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,501,677 shares of the biopharmaceutiMarch 2, 2024 | seekingalpha.comAmarin Corporation plc (AMRN) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comEarnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Trimming Their ForecastsMarch 1, 2024 | finance.yahoo.comAmarin Corporation plc (NASDAQ:AMRN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comAmarin’s Sell Rating Affirmed Amid Declining U.S. Sales and Uncertain International ExpansionFebruary 29, 2024 | fool.comAmarin Plc (AMRN) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | msn.comWhy Is Amarin Stock Trading Lower After Q4 Earnings?February 29, 2024 | finanznachrichten.deAmarin Corporation plc: Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 29, 2024 | msn.comAmarin Non-GAAP EPS of $0.00 beats by $0.03, revenue of $74.71M beats by $3.61MFebruary 29, 2024 | finance.yahoo.comAmarin Corp PLC (AMRN) Faces Revenue Decline Amidst Generic CompetitionFebruary 29, 2024 | globenewswire.comAmarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | msn.comAmarin Q4 2023 Earnings PreviewFebruary 15, 2024 | finance.yahoo.comAmarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024February 15, 2024 | marketbeat.comQ1 2025 EPS Estimates for Amarin Co. plc (NASDAQ:AMRN) Lifted by Zacks ResearchAmarin Co. plc (NASDAQ:AMRN - Free Report) - Equities researchers at Zacks Research boosted their Q1 2025 EPS estimates for shares of Amarin in a report issued on Monday, February 12th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will earn ($0.08) per share for thFebruary 15, 2024 | globenewswire.comAmarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024February 8, 2024 | marketbeat.comFY2023 Earnings Estimate for Amarin Co. plc (NASDAQ:AMRN) Issued By Leerink PartnrsAmarin Co. plc (NASDAQ:AMRN - Free Report) - Leerink Partnrs increased their FY2023 earnings per share estimates for Amarin in a report released on Monday, February 5th. Leerink Partnrs analyst R. Ruiz now anticipates that the biopharmaceutical company will post earnings per share of ($0.16) forFebruary 7, 2024 | marketbeat.comFY2027 Earnings Forecast for Amarin Co. plc Issued By Leerink Partnrs (NASDAQ:AMRN)Amarin Co. plc (NASDAQ:AMRN - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Amarin in a research note issued to investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical compaJanuary 31, 2024 | marketbeat.comAmarin Co. plc (NASDAQ:AMRN) Sees Large Decrease in Short InterestAmarin Co. plc (NASDAQ:AMRN - Get Free Report) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 12,800,000 shares, a decrease of 6.0% from the December 31st total of 13,620,000 shares. Based on an average daily volume of 2,300,000 shares, the short-interest ratio is currently 5.6 days. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden Nomination CANCELED? (Ad)The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words? I believe I have the terrifying answer right here. AMRN Media Mentions By Week AMRN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AMRN News Sentiment▼1.370.55▲Average Medical News Sentiment AMRN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AMRN Articles This Week▼22▲AMRN Articles Average Week Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ADC Therapeutics News Alto Neuroscience News Harrow News Corbus Pharmaceuticals News Erasca News Mereo BioPharma Group News Rani Therapeutics News Mersana Therapeutics News Terns Pharmaceuticals News Annexon News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AMRN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersThe 1,000X Crypto PlaybookTrue Market InsidersGold Set to EXPLODE!Gold Safe ExchangeCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMost important medical advance in 100 yearsThe Oxford ClubBill Clinton Backing Biden Replacement???The Freeport SocietyCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
